Total Payments
$15,080
2024 Payments
$3,429
Companies
24
Transactions
58
Medicare Patients
19,028
Medicare Billing
$13.7M
Payment Breakdown by Category
Consulting$10,781 (71.5%)
Research$1,927 (12.8%)
Food & Beverage$1,894 (12.6%)
Travel$322.76 (2.1%)
Education$155.08 (1.0%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $10,781 | 5 | 71.5% |
| Unspecified | $1,927 | 7 | 12.8% |
| Food and Beverage | $1,894 | 39 | 12.6% |
| Travel and Lodging | $322.76 | 3 | 2.1% |
| Education | $155.08 | 4 | 1.0% |
Payments by Type
General
$13,153
51 transactions
Research
$1,927
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $5,156 | 2 | $0 (2024) |
| BeiGene USA, Inc. | $3,102 | 6 | $0 (2022) |
| Taiho Oncology, Inc. | $1,925 | 1 | $0 (2020) |
| PFIZER INC. | $1,367 | 10 | $0 (2024) |
| Seagen Inc. | $1,100 | 1 | $0 (2020) |
| Takeda Pharmaceuticals U.S.A., Inc. | $784.37 | 6 | $0 (2019) |
| Janssen Biotech, Inc. | $369.40 | 4 | $0 (2024) |
| Genentech USA, Inc. | $262.86 | 3 | $0 (2022) |
| Advanced Accelerator Applications | $150.42 | 2 | $0 (2019) |
| Bayer HealthCare Pharmaceuticals Inc. | $124.99 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,429 | 17 | GENZYME CORPORATION ($2,909) |
| 2023 | $1,181 | 9 | PFIZER INC. ($949.34) |
| 2022 | $5,738 | 12 | BeiGene USA, Inc. ($3,102) |
| 2021 | $131.12 | 2 | Myovant Sciences Inc. ($119.62) |
| 2020 | $3,032 | 3 | Taiho Oncology, Inc. ($1,925) |
| 2019 | $594.46 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($321.60) |
| 2018 | $751.93 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($462.77) |
| 2017 | $221.38 | 2 | Millennium Pharmaceuticals, Inc. ($122.38) |
All Payment Transactions
58 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $19.29 | General |
| Category: Oncology | ||||||
| 10/30/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: ONCOLOGY | ||||||
| 10/09/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Oncology | ||||||
| 09/25/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $43.78 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 08/22/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $16.74 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $6.69 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Consulting Fee | Cash or cash equivalent | $2,909.00 | General |
| Category: Oncology | ||||||
| 07/09/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $31.80 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.11 | General |
| Category: Oncology | ||||||
| 05/16/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | In-kind items and services | $121.73 | General |
| Category: Oncology / Rare Diseases | ||||||
| 04/30/2024 | PFIZER INC. | INLYTA (Drug), IBRANCE, XTANDI | Food and Beverage | In-kind items and services | $19.51 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | In-kind items and services | $124.90 | General |
| Category: Oncology | ||||||
| 03/28/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $16.06 | General |
| Category: Oncology | ||||||
| 03/14/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: ONCOLOGY | ||||||
| 02/27/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $13.44 | General |
| Category: Oncology | ||||||
| 02/20/2024 | SERVIER PHARMACEUTICALS LLC | Tibsovo (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Oncology | ||||||
| 02/09/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $4.09 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $15.94 | General |
| Category: Hematology | ||||||
| 10/03/2023 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $9.34 | General |
| Category: ONCOLOGY | ||||||
| 09/18/2023 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI, CARVYKTI | Food and Beverage | In-kind items and services | $124.94 | General |
| Category: Oncology | ||||||
| 09/18/2023 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Oncology | ||||||
| 09/12/2023 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $15.80 | General |
| Category: Oncology | ||||||
| 09/07/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: Hematology | ||||||
| 08/08/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $16.02 | General |
| Category: ONCOLOGY | ||||||
| 03/31/2023 | AbbVie Inc. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ELRANATAMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $940.00 | 1 |
| Pevonedistat-3001 PANTHER North and Latin American Investigator Meeting - All Day Beverages 4-20 | Takeda Pharmaceuticals U.S.A., Inc. | $495.80 | 4 |
| NIROGACESTAT CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Participants With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL | Takeda Pharmaceuticals U.S.A., Inc. | $160.80 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 71 | 5,066 | 162,695 | $9.4M | $3.2M |
| 2022 | 76 | 5,426 | 187,700 | $10.8M | $3.8M |
| 2021 | 63 | 4,018 | 165,520 | $8.7M | $3.1M |
| 2020 | 67 | 4,518 | 165,070 | $9.1M | $3.6M |
Total Patients
19,028
Total Services
680,985
Medicare Billing
$13.7M
Procedure Codes
277
All Medicare Procedures & Services
277 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 35 | 31,500 | $2.9M | $1.2M | 40.7% |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2023 | 43 | 17,110 | $1.5M | $609,171 | 40.9% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 16 | 8,002 | $1.0M | $346,543 | 34.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 33 | 11,220 | $392,700 | $207,336 | 52.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 637 | 1,730 | $475,475 | $157,554 | 33.1% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 21 | 4,700 | $737,900 | $113,957 | 15.4% |
| Q5123 | Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 2023 | 20 | 3,100 | $486,700 | $106,562 | 21.9% |
| J1449 | Injection, eflapegrastim-xnst, 0.1 mg | Office | 2023 | 12 | 2,640 | $161,040 | $67,469 | 41.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 132 | 482 | $144,300 | $45,892 | 31.8% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 18 | 16,192 | $145,728 | $38,329 | 26.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 365 | 524 | $117,900 | $30,565 | 25.9% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 28 | 30,750 | $153,750 | $26,913 | 17.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 109 | 170 | $59,150 | $22,341 | 37.8% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 17 | 3,990 | $399,000 | $20,538 | 5.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 547 | 2,550 | $50,980 | $19,381 | 38.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 476 | 1,733 | $69,280 | $17,911 | 25.9% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 48 | 326 | $56,875 | $17,234 | 30.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 105 | 356 | $53,400 | $16,620 | 31.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 127 | 759 | $41,745 | $8,669 | 20.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 50 | 134 | $22,110 | $8,007 | 36.2% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 38 | 147 | $22,050 | $6,936 | 31.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 41 | 41 | $21,525 | $6,608 | 30.7% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 60 | 131 | $16,375 | $5,895 | 36.0% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 13 | 323 | $27,455 | $5,693 | 20.7% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 79 | 259 | $18,389 | $5,535 | 30.1% |
About Dr. Stefano Tarantolo, M.D
Dr. Stefano Tarantolo, M.D is a Hematology & Oncology healthcare provider based in Omaha, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1205816667.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stefano Tarantolo, M.D has received a total of $15,080 in payments from pharmaceutical and medical device companies, with $3,429 received in 2024. These payments were reported across 58 transactions from 24 companies. The most common payment nature is "Consulting Fee" ($10,781).
As a Medicare-enrolled provider, Tarantolo has provided services to 19,028 Medicare beneficiaries, totaling 680,985 services with total Medicare billing of $13.7M. Data is available for 4 years (2020–2023), covering 277 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Omaha, NE
- Active Since 01/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1205816667
Products in Payments
- SARCLISA (Biological) $5,156
- ADCETRIS (Biological) $1,100
- ELREXFIO (Drug) $940.00
- DARZALEX (Biological) $249.84
- IMBRUVICA (Drug) $161.12
- TECENTRIQ (Biological) $141.56
- LUTATHERA (Drug) $135.41
- Xofigo (Drug) $124.99
- NINLARO (Drug) $122.38
- AYVAKIT (Drug) $121.73
- Alecensa (Biological) $121.30
- ORGOVYX (Drug) $119.62
- IBRANCE (Drug) $65.43
- OPDUALAG (Drug) $62.64
- ZENPEP (Drug) $43.78
- IDHIFA (Drug) $43.44
- Vonjo (Drug) $32.30
- Tibsovo (Drug) $24.47
- VENCLEXTA (Drug) $22.24
- EPKINLY (Drug) $21.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Omaha
James Armitage, Md, MD
Hematology & Oncology — Payments: $1.5M
Hematology & Oncology $1.5M
Margaret Block, M.d, M.D
Hematology & Oncology — Payments: $444,214
Hematology & Oncology $444,214
Julie Vose, Md, MD
Hematology & Oncology — Payments: $194,187
Hematology & Oncology $194,187
Peter Silberstein, M.d, M.D
Hematology & Oncology — Payments: $143,878
Hematology & Oncology $143,878
Apar Kishor Ganti, Md, MD
Hematology & Oncology — Payments: $135,871
Hematology & Oncology $135,871
Dr. Krishna Gundabolu, M.d, M.D
Hematology & Oncology — Payments: $75,519
Hematology & Oncology $75,519